Gold vs US Dollar

Register to chat with like-minded investors on our interactive forums.

Get Started

Disperse Tech Investors - DPT

Share Name	Share Symbol	Market	Stock Type
Disperse Tech	DPT	London	Ordinary Share

	Price Change	Price Change %	Share Price	Last Trade
	0.00	0.00%		-

Open Price	Low Price	High Price	Close Price	Previous Close

more quote information »

Top Investor Posts

Top Posts
Posted at 27/1/2005 19:06 by rambutan2 spose everyone except for me had noticed that the disperse web site has been updated/refashioned. these for my ref... 20/04/01 Major Licence Agreement With Bath & Body Works Inc. 10 October 2001 Major licence agreement signed Disperse Technologies is pleased to announce that it has signed a licensing deal with Shiseido America Inc - the USA subsidiary of the Shiseido Company of Japan, the world's fourth largest cosmetics company, with world-wide group sales of $5.4 billion in fiscal 2000. Initially the license is intended for US developed and manufactured brands which are a key area in Shiseido's corporate development plans. For more information see: www.shiseido.co.jp Disperse Technologies has also signed a Letter of Intent with Davlyn Industries Inc, a sister company of Shiseido America Inc, which is a major third party manufacturer of cosmetics and toiletries, with the intention of granting Davlyn a licence to use Disperse's technologies in products manufactured for other companies. Disperse Technologies would like to emphasise that it is unlikely that any significant income will accrue from any of the above agreements before calendar year 2003 at the earliest. Derek Wheeler, Chief Executive of Disperse, said: "We are delighted to be associated with Shiseido America Inc and Davlyn Industries Inc who should provide a significant widening of our activities in the USA. In addition I am confident that we will be able to announce further agreements in the coming months with a number of different companies. These are exciting times for the teams who work in our research centres in both the UK and USA and I would like to thank them for their dedication and commitment." 13 December 2001 Licence agreement signed with Nu Skin Enterprises Inc Disperse Technologies announces that it has signed an agreement with Nu Skin International ("Nu Skin"), a subsidiary of Nu Skin Enterprises Inc., to license its ATD technology. Nu Skin Enterprises, with nearly $900 million in global sales, is a world leader in the creation and distribution of personal care products with an emphasis on skin care. Founded in 1984, Nu Skin has expanded into more than 30 countries throughout the Americas, the Asia Pacific region and Europe with products being sold one-to-one by over 500,000 active distributors. The corporate headquarters are located in Provo, Utah - 40 miles south of Salt Lake City. The company's stock is traded on the New York Stock Exchange under the symbol "NUS". See www.nuskin.com and www.nuskinenterprises.com. Derek Wheeler, the Chief Executive Officer of Disperse Technologies, commented: "Nu Skin is one of the most respected names in skin care and I am delighted that they have chosen to license our technology to further enhance the quality of their fine products. We look forward to doing increasing business with them over the coming years. Once again, I would like to emphasize to our investors that it must be remembered that we only receive income once commercial production by our licensees has commenced and that substantial income streams may take at least 12-18 months to come through." 22 January 2002 Licence Agreement Signed With Nice-Pak International Limited Disperse Technologies is pleased to announce that it has signed a Licence Agreement with Nice-Pak International Limited, the UK arm of Nice-Pak Products, one of the world's leading suppliers of wet wipes. Nice-Pak International Limited started trading in the UK in 1987. The Group employs over 1000 people in plants in USA and UK. Today, the Nice-Pak International Limited plant in Flint produces a large proportion of all the wet wipes used in the UK and Europe as well as the bulk of retailer brand wet wipes. Derek Wheeler, the Chief Executive Officer of Disperse Technologies, said: "I am very pleased to announce our first Licence deal of 2002 which is the first success of our European sales campaign initiated in the second half of 2001. We believe that our technologies will complement those of Nice-Pak International Limited and we look forward to a long and fruitful relationship between our two companies." 17 March 2003 Major Licence Agreement with Cosmetic Essence, Inc Disperse Technologies Inc, based in Paramus, New Jersey, the wholly owned US subsidiary of Guildford based Disperse Technologies, announces the signing of a licence agreement between Cosmetic Essence, Inc and Disperse Limited. Cosmetic Essence, Inc. ("Cosmetics Essence"), headquartered in Holmdel, New Jersey, is a leading provider of outsourced manufacturing, filling, packaging, and distribution services to the $29 billion U.S. personal care products industry. It specialises in providing product formulation, finished product manufacturing, and subsequent full-service distribution, and has a diversified customer base ranging from branded fragrance and cosmetics marketers to mass-merchant and specialty retailers. By offering some the largest retailers in the US a complete range of services for alcohol-based, skin care, and colour cosmetics products, Cosmetic Essence has established itself as one of the industry's largest and most versatile contract manufacturers in the North American market. Colston Herbert, the Executive Chairman of Disperse, said: "We are delighted that Disperse Technologies Inc in its new role as the Disperse Technologies Group sales agent in the USA has secured its first licence on behalf of Disperse limited with one of the major cosmetics manufacturers in North America. This agreement should, in due course, significantly increase the sales of cosmetics products using our leading edge ATD technology. I would like to emphasise that is unlikely that any significant income will accrue from this agreement before the end calendar year 2004 at the earliest." march 03 newsletter: Estée Lauder, Bath & Body Works and Davlyn all plan to launch new products containing our technologies this year. Meanwhile, presentations and discussions are ongoing with a number of other potential customers in the USA, Europe and Japan. One significant change in our sales approach has been the adoption of product licensing (rather than technology licensing). This approach involves agreeing a general licensing principle with our customers but then agreeing terms for each individual product they wish to launch. This gives us opportunities for greater control, more flexibility on pricing and quicker exploitation (although the actual licence agreement process may take a little longer). Generally, we have found more enthusiasm from potential licensees for product rather than technology licenses. Our first licences for the use of our TFE technology should be finalised during the next few months. Emulsion Systems Limited Newly re-formed under the guidance of our David Gladman, Emulsion Systems Limited (EMSYS) has begun the process of exploiting XME technology in a variety of industries. David has overseen the construction and development of bench-top and pilot-scale XME units and is busy making presentations and demonstrations in the specially appointed chemical engineering lab at Guildford. Brian Clark, an experienced sales and marketing consultant in the field of processing equipment, has joined him. EMSYS has now attracted the attention of a number of major European and American companies - the pilot- scale model is undergoing trials in the USA with a large US company as I write. More information can be obtained from the website at www.emulsionsystems.com aug 03 newsletter: Change is very much in the air at Disperse. Until now, our business strategy has been to license our technologies to very large companies in return for royalties and it has provided us with an annual income of over £1 million. However, the rate of income growth has been slower than we would like. This is because large companies cannot adopt technologies as novel as ours with the speed that we had initially hoped and anticipated. Of course, licensing of this kind will continue to play an important and expanding part of our future business and we are in the process of meaningful negotiations with several of the world's largest cosmetics and household goods manufacturers. However, your Board has charged us with the task of finding additional ways to exploit our world-class technologies - ways that will give us an even better and speedier return on our R&D investment. Read Full Thread Reply
Posted at 08/12/2004 20:16 by blank frank In view of the constant negativity and partiality of BigT20 it's no wonder that investors are gaining a distorted view, and are considering leaving. Please be aware that I have a good idea of the identity of BigT20, which I will keep confidential, but will say that he is a notoriously negative person. The very fact that he apparently went to the results presentation (which he has not denied) and is too selfish &/or lazy to give one word of feedback speaks volumes for his mentality. [In contrast, I posted a very lengthy write-up of the July floatation presentation. ] The unique thing about DPT (for its valuation) is that it has a lot of jam tomorrow AND plenty of jam today, whereas normally you would have to make a choice. The important here and now things are:- * Regular Estee Lauder licensing income of c. £1M. p.a. * Successful launch of Elizabeth French's VIVO range, which should mean EF profits of c. £2M. in 2006. * Launch of new BBW product range, which could double Disperse's licensing income; and new Estee Lauder product launch. * The imminent Virgin Vie product launches. These things alone should give DPT millions of pounds of profit and good multi-bagger status within two or three years, even if none of the jam tomorrow starts to roll in. It's rather ironic that DPT would apparently be viewed more positively, and perhaps have a higher valuation, if it only had the here and now stuff, and the other possibilities didn't even exist, so that people couldn't worry about them not happening (soon enough)! So please don't go! B.F. P.S. DPT also owns 10% of K B Innovations Group, which stake alone, even ignoring all DPT's own technologies, could be worth very many times DPT's current capitalisation. Read Full Thread Reply
Posted at 07/12/2004 20:11 by blank frank BigT20 - 7 Dec'04 - 09:34 - 134 of 134 "Given the context of Reckitt & Benckiser new product launches in recent years, you explain Disperse's pathetic performance regarding that licence ." Investors Chronicle" 3rd. September 2004, under Antonov:- "Major developments in the automotive industry can take as long as 15 years to come to fruition. And that is how long it will be before Antonov, set up in 1991, begins to earn royalties on its smaller and lighter gearboxes." Let's be realistic about product development timescales. Disperse's licencees may not take 15 years, but a few years seems quite reasonable. And if Disperse's technology can enable them to produce products more cheaply, and even make them more effective, it stands to reason that they will use that technology. B.F. Read Full Thread Reply
Posted at 29/11/2004 19:43 by blank frank The 19/11/04 "Investors Chronicle", which tipped DPT as a buy, also contained an interesting article entitled "Exceptional Returns" which is also relevant to DPT. The IC's research suggests that firms with exceptional losses tend to beat the market:- " ... investing in shares of the 10 companies with the biggest negative one-off items [relative to their adjusted earnings] would also have made good returns. Overall, this strategy beat the market by an average of 7.5 per cent in the following 12-month period ... Hanging on to either group of shares for longer produces even better results. [Actually, average of 10.2% total outperformance over 3 years (i.e. not 10.2% p.a.).] ... The lessons here seem clear enough. While investors focus on the earnings figure and ignore the exceptionals, out findings suggest it would be better to concentrate on the exceptionals and ignore the earnings." High exceptional costs have reduced DPT's 2004 results. These should not recur, but I don't think that fact is yet being reflected in the share price. B.F. Read Full Thread Reply
Posted at 19/11/2004 19:26 by blank frank The full "Investors Chronicle" article:- TIPS SMALLER COMPANIES cosmetics DISPERSE TECHNOLOGIES (DPT) ^BUY Disperse was originally formed in 1995 by Derek Wheeler to exploit technological advances made in the cosmetics industry that enabled more efficient production and a lower concentration of additives and preservatives. Since then, the company has signed up several high-profile licensees, including Estee Lauder and US personal-care retailer Bath & Body Works. But with margins for licensing the technology low, Disperse decided to move into the retail end of the market with the acquisition of cosmetics brand owner Elizabeth French in July 2004 for a maximum consideration of £9m. That deal was combined with a move from Ofex to Aim and a £4.7m fund-raising. It's still early days for that acquisition, but the signs are already encouraging. Full-year figures for the year to 31 August 2004 include only one month's trading from Elizabeth French but, in that period, it accounted for more than two-thirds of total sales. Broker JM Finn forecasts that Disperse's sales should jump to £16m in 2005 and nearly £18m in 2006. Much of the growth will be achieved through rationalisation. Disperse's management already has experience in implementing cost savings, having cut nearly £1m out of the technology business. Once it gets to work on Elizabeth French, the improvements should be marked. At the same time, extension and development of the existing Elizabeth French range is planned. The 2005 PE ratio of 10 falls to just 6 for the following year - that's cheap for a company with such huge growth potential. Buy. BULL POINTS * Recent acquisition has generated significant potential for growth. * Costs have been cut. BEAR POINTS * Tech licensing business is low-margin. DISPERSE TECHNOLOGIES Aim ORD PRICE:19p MARKET VALUE:£11M TOUCH:17-20.5 12-MONTH HIGH:20P LOW:16P DIVIDEND YIELD:nil PE RATIO:10* NET ASSET VALUE:12P NET DEBT:6% YEAR TO TURNOVER PRE-TAX EARNINGS PER DIVIDEND PER 31 AUGUST (£M) PROFIT(£M) SHARE (P) SHARE (P) 2004 2.81 -0.57 -2.62 nil 2005* 15.99 0.74 1.95 nil % change +469 Market makers:4 Normal market size:10,000 *JM Finn's estimates Last IC view: 13 Feb 2004, page 69 Read Full Thread Reply
Posted at 09/11/2004 20:48 by blank frank This extract from the Chairman's Report was interesting:- "We received our first design and supply order for two new products for a prestige UK brand for delivery early 2005. We are currently negotiating with other companies both in the UK and the USA to develop this particular aspect of our business as an alternative to our traditional royalty remuneration." We can usefully speculate who that first company might be, if you read my notes from Disperse's 13/7/04 presentation in London:- "Virgin Vie are launching products using Disperse's technology early in 2005. In this case, Disperse will be providing the finished products, rather than VV formulating the products themselves: this will give Disperse much better margins on these products. This is more important for UK licencees, because the products sales are much smaller than with US licencees." Follow-up comment by Fez two days later:- "3) Virgin Vie is good news - for VV too - I know a couple of people who thought their products looked excellent but when they used them they could be quite nasty to the skin (in particular)" So how are Virgin Vie doing? Very well apparently, according to the 22/10/04 "Investors Chronicle":- "Little-known Victory Corporation has suddenly become one of Sir Richard Branson's profitable projects - and with no publicity from him. Until last year, Victory had been reporting losses - nearly £39m in the previous four years - but, in 2003-04, it traded its way out of deficit. Specifically, the retail and direct sales activities turned in an operating profit of £3.29m, compared with a loss of £1.28m in the previous year, before exceptional costs of £1.32m. The key to the business is Virgin Cosmetics Direct, with largely fixed overheads and variable commission payments. It accounted for 84 per cent of cosmetics sales and increased last year's sales by 38 per cent. Behind those figures was a one-quarter rise - to nearly 10,000 - in the number of self-employed consltants. They held more than 211,000 "classes" which were attended by almost 2m customers. Each has his or her own website. New products accounted for more than a third of sales, including Out of Sight optical brighteners to smooth away wrinkles and Icon and Goddess bath and body lines. Men's products, including after shaves and balms, accounted for 12 per cent of sales growth. In July, Victory paid back a Virgin loan of £8.4m, following a £10.1m open offer at 170p. Brokers hope for 2004-05 sales of over £72m and profits of around £4.5m. IC VIEW. The shares have doubled this year and are tightly held, but they are still a buy. ORD PRICE: 360p MARKET VALUE: £40.7m ... YEAR TO 31 MAR 2004 TURNOVER £64.3M PRE-TAX PROFIT £2.11M" Read Full Thread Reply
Posted at 13/10/2004 17:12 by blank frank Big T20, I didn't actually comment on the size of the buying; to quote from my 11th. October post:- "Fresh buying is being attracted on the back of the HB note, and in anticipation of the coming final results." You're correct that the buying volumes aren't huge in absolute terms, but then neither were the August selling volumes that pushed the price down to from 17.5 to 16p. It's unlikely that institutions will be buing more yet as it's so soon after the placing, which means that any dealing is likely to be retail investors. But for retail investors, some of those buys have been quite large. Bearing in mind that some individuals may invest as little as c. £500 into a single stock (the minimum sub per person in the recent offer was just £540), then a buy of c. £15K. is about thirty times that amount. Not that many people buying yet it's true - the Disperse story hasn't got out that much more yet, and most existing followers will probably have topped up adequately in the offer. But even just a few more people having the confidence and encouragement to come in and buy at this comparatively early stage is a good sign for the future. As is the investment by Colston. B.F. Read Full Thread Reply
Posted at 19/9/2004 20:38 by doubleorquits Broker note out 15th Sept, although I see it was written on July 28th so not new. https://www.hoodlessbrennan.com/secure/user/research.asp The £11m valuation offers investors an opportunity to buy into an emerging but already proven technology early into its product lifecycle. Although loss making to date its core licensing business could become lucrative if one or more of the deals under negotiation come to fruition. The pharmaceutical applications offer potential for further upside in the short to medium term for derma products and in the longer term for oral delivery systems. The acquisition of Elizabeth French will bring the company cashflow positive which is highly unusual for a company still so focussed on R&D. The company has indicated that further acquisitions are likely. A forward PE of 8.41x for 05 and 2.59x to 06 per house broker projections suggest that the 80% premium to net asset value is well warranted. SPECULATIVE BUY Interesting to note that the PE for YE Dec is 8.41 and if this is achieved, or looks like being achieved, then DPT will prove grossly undervalued IMO. Proven technology so that limits the risk there but it will need newsflow and preferably nice licences and agreements with some big companies. Nevertheless a forward PE of only just over 8 will make me top up my limited holding from the Ofex days if things look promising at the turn of the year. Read Full Thread Reply
Posted at 01/9/2004 08:55 by fez .....odd that Colston decided after the issue that buying more shares would be a good idea....positive indicator nonetheless... Disperse Technologies Group PLC 31 August 2004 Disperse Technologies Group PLC Disperse Technologies Group plc (the 'Company') has, subsequent to its Placing, Offer for subscription and Admission to AIM of 26 July 2004, placed with investors a further 153,728 ordinary shares in the Company at 18p per share. This brings the total issued share capital of the Company to 60,864,263 ordinary shares. Application will be made for the new ordinary shares to be admitted to AIM and trading is expected to commence on 7 September 2004. Following the increase in issued share capital as above, the shareholding in the Company's shares by Mr Colston Herbert (Chairman) has increased by 88,839 shares to 265,227 ordinary shares or 0.44% of the enlarged issued share capital. 31 August 2004 Read Full Thread Reply

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions